Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...

Biocon Biologics plans to raise ₹4,500 crore with HSBC and MUFG's aid for a $175 million Aflibercept option. Previous funding by Kotak and ...

The fund plans to provide a $150 million mezzanine debt facility at 18-20% and arrange another $300 million from other lenders to finance t...

The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded...

Biocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...

EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. ...

India's Kotak Mahindra Group asset management arm said on Wednesday it will invest 10.70 billion rupees ($129 million) in Biocon Ltd to hel...

"There are several other discussions that we have been having with private equity investors who are interested in making an investment in B...

To fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...

At the time of announcing the deal to acquire Viatris, BBL had said it would be through a cash payment of USD 2 billion, which would be fun...

The transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...

Biocon Biologics in March entered into a definitive agreement to acquire Viatris' biosimilars assets for $3.34 billion. It will pay Viatris...

Out of $2 billion, $800 million will come through equity infusion from existing investors including parent Biocon and others such as Serum ...

Biocon Biologics, a unit of Biocon, is raising $1.2 billion via an offshore loan with the pharmaceutical company likely appointing HSBC, MU...

The $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...

Biocon Biologics (BBL) will get the global biosimilar business of Viatris in developed and emerging markets, with an estimated revenue of $...

BBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...